LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Search

Insulet Corp

Gesloten

SectorGezondheidszorg

153.31 4.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

146.34

Max

154.16

Belangrijke statistieken

By Trading Economics

Inkomsten

-11M

91M

Verkoop

-22M

762M

K/W

Sectorgemiddelde

34.61

49.888

EPS

1.3

Winstmarge

11.96

Werknemers

5,400

EBITDA

-23M

154M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+59.63% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.6B

10B

Vorige openingsprijs

148.51

Vorige sluitingsprijs

153.31

Nieuwssentiment

By Acuity

25%

75%

64 / 344 Rangschikking in Healthcare

Insulet Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 mei 2026, 19:47 UTC

Winsten

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

Peer Vergelijking

Prijswijziging

Insulet Corp Prognose

Koersdoel

By TipRanks

59.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 233.72 USD  59.63%

Hoogste 294 USD

Laagste 165 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Insulet Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

17

Buy

3

Hold

1

Sell

Sentiment

By Acuity

64 / 344 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat